LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

LLY

1,064.11

+2.13%↑

JNJ

234.43

+1.74%↑

ABBV

216.94

+0.77%↑

UNH

388.84

+1.3%↑

AZN

188.07

-0.94%↓

Search

Bio-Techne Corp

Open

BrancheGesundheitswesen

47.97 1.59

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

46.87

Max

48.09

Schlüsselkennzahlen

By Trading Economics

Einkommen

13M

51M

Verkäufe

16M

311M

KGV

Branchendurchschnitt

63.471

49.701

EPS

0.53

Dividendenrendite

0.74

Gewinnspanne

16.392

Angestellte

3,100

EBITDA

22M

100M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+26.87% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.74%

2.39%

Nächstes Ergebnis

5. Aug. 2026

Nächste Dividendenausschüttung

29. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.6B

7B

Vorheriger Eröffnungskurs

46.38

Vorheriger Schlusskurs

47.97

Nachrichtenstimmung

By Acuity

50%

50%

148 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Bio-Techne Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Nov. 2025, 22:36 UTC

Ergebnisse

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Peer-Vergleich

Kursveränderung

Bio-Techne Corp Prognose

Kursziel

By TipRanks

26.87% Vorteil

12-Monats-Prognose

Durchschnitt 59.25 USD  26.87%

Hoch 70 USD

Tief 49 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bio-Techne Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

10 ratings

6

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

49.67 / 50.24Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

148 / 345 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat